Recommended Topic Related To:

Trelstar

"The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for"...

Trelstar

Trelstar Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Trelstar (triptorelin pamoate) for Injectable Suspension is a gonadotropin releasing hormone (GnRH) for the palliative treatment of advanced prostate cancer. Common side effects include flushing, bone pain, nerve pain, impotence, blood in urine, and difficulty urinating.

Trelstar is administered by a single intramuscular injection in either buttock. Dosing schedule depends on the product strength selected. Trelstar may interact with other drugs. Tell your doctor all medications and supplements you use. Trelstar is not indicated for use in women and is therefore unlikely to be used during pregnancy while breastfeeding; consult your doctor.

Our Trelstar (triptorelin pamoate) for Injectable Suspension Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Trelstar FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of the three TRELSTAR formulations was evaluated in clinical trials involving patients with advanced prostate cancer. Mean testosterone levels increased above baseline during the first week following the initial injection, declining thereafter to baseline levels or below by the end of the second week of treatment. The transient increase in testosterone levels may be associated with temporary worsening of disease signs and symptoms, including bone pain, neuropathy, hematuria, and urethral or bladder outlet obstruction. Isolated cases of spinal cord compression with weakness or paralysis of the lower extremities have occurred [see WARNINGS AND PRECAUTIONS

Adverse reactions reported for each of the three TRELSTAR formulations in the clinical trials, are presented in Table 2, Table 3, and Table 4. Often, causality is difficult to assess in patients with metastatic prostate cancer. The majority of adverse reactions related to triptorelin are a result of its pharmacological action, i.e., the induced variation in serum testosterone levels, either an increase in testosterone at the initiation of treatment, or a decrease in testosterone once castration is achieved. Local reactions at the injection site or allergic reactions may occur.

The following adverse reactions were reported to have a possible or probable relationship to therapy as ascribed by the treating physician in at least 1% of patients receiving TRELSTAR 3.75 mg.

Table 2: TRELSTAR 3.75 mg: Treatment-Related Adverse Reactions Reported by 1% or More of Patients During Treatment

* Adverse Reactions TRELSTAR 3.75 mg
N =140
N %
Application Site Disorders
  Injection site pain 5 3.6
Body as a Whole
  Hot flush 82 58.6
  Pain 3 2.1
  Leg pain 3 2.1
  Fatigue 3 2.1
Cardiovascular Disorders
  Hypertension 5 3.6
Central and Peripheral Nervous System Disorders
  Headache 7 5.0
  Dizziness 2 1.4
Gastrointestinal Disorders
  Diarrhea 2 1.4
  Vomiting 3 2.1
Musculoskeletal System Disorders
  Skeletal pain 17 12.1
Psychiatric Disorders
  Insomnia 3 2.1
  Impotence 10 7.1
  Emotional lability 2 1.4
Red Blood Cell Disorders
  Anemia 2 1.4
Skin and Appendages Disorders
  Pruritus 2 1.4
Urinary System Disorders
  Urinary tract infection 2 1.4
  Urinary retention 2 1.4
* Adverse reactions for TRELSTAR 3.75 mg are coded using the WHO Adverse Reactions Terminology (WHOART)

The following adverse reactions were reported to have a possible or probable relationship to therapy as ascribed by the treating physician in at least 1% of patients receiving TRELSTAR 11.25 mg.

Table 3: TRELSTAR 11.25 mg: Treatment-Related Adverse Reactions Reported by 1% or More of Patients During Treatment

Adverse Reactions* TRELSTAR 11.25 mg
N =174
N %
Application Site
  Injection site pain 7 4.0
Body as a Whole
  Hot flush 127 73.0
  Leg pain 9 5.2
  Pain 6 3.4
  Back pain 5 2.9
  Fatigue 4 2.3
  Chest pain 3 1.7
  Asthenia 2 1.1
  Peripheral edema 2 1.1
Cardiovascular Disorders
  Hypertension 7 4.0
  Dependent edema 4 2.3
Central and Peripheral Nervous System Disorders
  Headache 12 6.9
  Dizziness 5 2.9
  Leg cramps 3 1.7
Endocrine
  Breast pain 4 2.3
  Gynecomastia 3 1.7
Gastrointestinal Disorders
  Nausea 5 2.9
  Constipation 3 1.7
  Dyspepsia 3 1.7
  Diarrhea 2 1.1
  Abdominal pain 2 1.1
Liver and Biliary System
  Abnormal hepatic function 2 1.1
Metabolic and Nutritional Disorders
  Edema in legs 11 6.3
  Increased alkaline phosphatase 3 1.7
Musculoskeletal System Disorders
  Skeletal pain 23 13.2
  Arthralgia 4 2.3
  Myalgia 2 1.1
Psychiatric Disorders
  Decreased libido 4 2.3
  Impotence 4 2.3
  Insomnia 3 1.7
  Anorexia 3 1.7
Respiratory System Disorders
  Coughing 3 1.7
  Dyspnea 2 1.1
  Pharyngitis 2 1.1
Skin and Appendages
  Rash 3 1.7
Urinary System Disorders
  Dysuria 8 4.6
  Urinary retention 2 1.1
Vision Disorders
  Eye pain 2 1.1
  Conjunctivitis 2 1.1
*Adverse reactions for TRELSTAR 11.25 mg are coded using the WHO Adverse Reactions Terminology (WHOART)

The following adverse reactions occurred in at least 5% of patients receiving TRELSTAR 22.5 mg. The table includes all reactions whether or not they were ascribed to TRELSTAR by the treating physician. The table also includes the incidence of these adverse reactions that were considered by the treating physician to have a reasonable causal relationship or for which the relationship could not be assessed.

Table 4: TRELSTAR 22.5 mg: Adverse Reactions Reported by 5% or More of Patients During Treatment

Adverse Reactions* TRELSTAR 22.5 mg
N = 120
Treatment-Emergent Treatment-Related
N % N %
General Disorders and Administration Site Conditions
  Edema peripheral 6 5.0 0 0
Infections and Infestations
  Influenza 19 15.8 0 0
  Bronchitis 6 5.0 0 0
Endocrine
  Diabetes Mellitus/Hyperglycemia 6 5.0 0 0
Musculoskeletal and Connective Tissue Disorders
  Back pain 13 10.8 1 0.8
  Arthralgia 9 7.5 1 0.8
  Pain in extremity 9 7.5 1 0.8
Nervous SystemDisorders
  Headache 9 7.5 2 1.7
Psychiatric Disorders
  Insomnia 6 5.0 1 0.8
Renal and Urinary Disorders
  Urinary tract infection 14 11.6 0 0
  Urinary retention 6 5.0 0 0
Reproductive Systemand Breast Disorders
  Erectile dysfunction 12 10.0 12 10.0
  Testicular atrophy 9 7.5 9 7.5
Vascular Disorders
  Hot flush 87 72.5 86 71.7
  Hypertension 17 14.2 1 0.8
*Adverse reactions for TRELSTAR 22.5 mg are coded using the Medical Dictionary for Regulatory Activities (MedDRA)

Changes in Laboratory Values During Treatment

The following abnormalities in laboratory values not present at baseline were observed in 10% or more of patients:

TRELSTAR 3.75 mg: There were no clinically meaningful changes in laboratory values detected during therapy.

TRELSTAR 11.25 mg: Decreased hemoglobin and RBC count and increased glucose, BUN, SGOT, SGPT, and alkaline phosphatase at the Day 253 visit.

TRELSTAR 22.5 mg: Decreased hemoglobin and increased glucose and hepatic transaminases were detected during the study. The majority of the changes were mild to moderate.

Postmarketing Experience

The following adverse reactions have been identified during post approval use of gonadotropin releasing hormone agonists. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

During postmarketing surveillance, rare cases of pituitary apoplexy (a clinical syndrome secondary to infarction of the pituitary gland) have been reported after the administration of gonadotropin-releasing hormone agonists. In a majority of these cases, a pituitary adenoma was diagnosed with a majority of pituitary apoplexy cases occurring within 2 weeks of the first dose, and some within the first hour. In these cases, pituitary apoplexy has presented as sudden headache, vomiting, visual changes, ophthalmoplegia, altered mental status, and sometimes cardiovascular collapse. Immediate medical attention has been required.

During postmarketing experience, convulsions, and thromboembolic events including, but not limited to, pulmonary emboli, cerebrovascular accident, myocardial infarction, deep venous thrombosis, transient ischemic attack, and thrombophlebitis have been reported.

Read the entire FDA prescribing information for Trelstar (Triptorelin Pamoate for Injectable Suspension) »

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Cancer

Get the latest treatment options.